- Home
- IPSC vs NVNI Comparison
IPSC vs NVNI Comparison
Compare IPSC & NVNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- NVNI
- Stock Information
- Founded
- IPSC 2019
- NVNI 2019
- Country
- IPSC United States
- NVNI Brazil
- Employees
- IPSC N/A
- NVNI N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- NVNI
- Sector
- IPSC Health Care
- NVNI
- Exchange
- IPSC Nasdaq
- NVNI Nasdaq
- Market Cap
- IPSC 49.1M
- NVNI 57.2M
- IPO Year
- IPSC 2021
- NVNI N/A
- Fundamental
- Price
- IPSC $0.57
- NVNI $4.12
- Analyst Decision
- IPSC Strong Buy
- NVNI
- Analyst Count
- IPSC 5
- NVNI 0
- Target Price
- IPSC $3.33
- NVNI N/A
- AVG Volume (30 Days)
- IPSC 730.7K
- NVNI 1.4M
- Earning Date
- IPSC 11-04-2025
- NVNI 09-30-2025
- Dividend Yield
- IPSC N/A
- NVNI N/A
- EPS Growth
- IPSC N/A
- NVNI N/A
- EPS
- IPSC N/A
- NVNI N/A
- Revenue
- IPSC $114,128,000.00
- NVNI $31,250,627.00
- Revenue This Year
- IPSC $1,589.94
- NVNI $12.05
- Revenue Next Year
- IPSC N/A
- NVNI $15.02
- P/E Ratio
- IPSC N/A
- NVNI N/A
- Revenue Growth
- IPSC 5491.77
- NVNI 1491.58
- 52 Week Low
- IPSC $0.34
- NVNI $1.44
- 52 Week High
- IPSC $1.83
- NVNI $121.90
- Technical
- Relative Strength Index (RSI)
- IPSC 60.85
- NVNI 71.98
- Support Level
- IPSC $0.52
- NVNI $2.96
- Resistance Level
- IPSC $0.62
- NVNI $3.67
- Average True Range (ATR)
- IPSC 0.03
- NVNI 0.46
- MACD
- IPSC 0.01
- NVNI 0.27
- Stochastic Oscillator
- IPSC 64.94
- NVNI 82.10
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.